Soluble interleukin-2 receptor in cancer
Soluble interleukin-2 receptor in cancer
复制标题
DOI：
10.2741/1461
复制
发表时间：
2004-09-01
影响因子：
3.1
通讯作者：
Murakami, S
中科院分区：
文献类型：
--
作者：
Murakami, S
血清sIL-2 R（可溶性白细胞介素-2受体）水平反映了癌组织和转移器官的肿瘤浸润淋巴细胞中活化的T淋巴细胞的总量，因为IL-2 R的一部分α链在IL-2（白细胞介素-2）附着到其特异性IL-2 R膜上时释放到血流中。在大多数恶性疾病中，发现血清sIL-2 R水平与正常对照相比升高。血清sIL-2 R虽不是器官特异性指标，但可作为评估疾病分期和监测治疗后随访疾病进展的有用指标。
Levels of serum sIL-2R ( soluble interleukin-2 receptor) reflect the total amount of activated T lymphocytes in tumor infiltrating lymphocytes of cancer tissues and metastatic organs, because a part of alpha-chain of IL-2R is released into the bloodstream on the attachment of IL-2 (interleukin-2) to its specific IL-2R membrane. In most malignant diseases, elevated levels of serum sIL-2R are found, compare to normal control. Serum sIL-2R is a useful parameter for evaluating the disease stage and monitoring the disease progression during the posttreatment follow-up, though it is not an organ-specific parameter.